The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $402.49, representing a -1.13% change from its previous close.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

(“Vertex” or the “Company”), a global provider of tax technology solutions, has been named a Leader in three IDC MarketScape reports: IDC MarketScape: Worldwide SaaS and Cloud-Enabled SaaS ...

Vertex remains a trusted partner for organizations worldwide, reinforcing its leadership in an increasingly digitized tax management space. By staying at the forefront of tax technology ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex, Inc., a leading provider of tax technology solutions, has been recognized as a Leader in three recent IDC MarketScape reports assessing SaaS and cloud-enabled tax automation software for ...

This was the stock's third consecutive day of gains.

Vertex Global Services partners with UK-based Arish Global Services to create over 5,000 jobs in India, boosting the ...

The VERTEX 80/80v optics design allows PEAK flexibility and PEAK instrument performance at the same time. The unique Bruker Optics DigiTect ™ technology ensures PEAK signal-to-noise ratio ...

The french-fry maker replaced its chief executive and [slashed guidance again]( ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...